Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 1. Prevalence of undocumented hepatitis C virus (HCV) infection, by age, race, and sex in 4713 emergency department patients, 2013. From: Evaluation.

Published bySylvia Baldwin Modified over 6 years ago

Similar presentations

Presentation on theme: "Figure 1. Prevalence of undocumented hepatitis C virus (HCV) infection, by age, race, and sex in 4713 emergency department patients, 2013. From: Evaluation."— Presentation transcript:

1 Figure 1. Prevalence of undocumented hepatitis C virus (HCV) infection, by age, race, and sex in 4713 emergency department patients, 2013. From: Evaluation of the Centers for Disease Control and Prevention Recommendations for Hepatitis C Virus Testing in an Urban Emergency Department Clin Infect Dis. 2016;62(9): doi: /cid/ciw074 Clin Infect Dis | © The Author Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions,

2 Figure 2. Distribution of 204 undocumented hepatitis C virus infections, by baby boomer birth cohort (1945–1965), human immunodeficiency virus (HIV) serostatus, and injection drug use (IDU) status. From: Evaluation of the Centers for Disease Control and Prevention Recommendations for Hepatitis C Virus Testing in an Urban Emergency Department Clin Infect Dis. 2016;62(9): doi: /cid/ciw074 Clin Infect Dis | © The Author Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions,

Download ppt "Figure 1. Prevalence of undocumented hepatitis C virus (HCV) infection, by age, race, and sex in 4713 emergency department patients, 2013. From: Evaluation."

Similar presentations

To enhance students ability to interpret data in charts and graphs To discuss basic concepts in epidemiology and science.

To enhance students ability to interpret data in charts and graphs To discuss basic concepts in epidemiology and science.
Fig. 3. Plot of overall survival by adjuvant therapy for patient subgroups. (A) Patients with M0 disease (n = 411). (B) Patients receiving 36 Gy craniospinal.

Fig. 3. Plot of overall survival by adjuvant therapy for patient subgroups. (A) Patients with M0 disease (n = 411). (B) Patients receiving 36 Gy craniospinal.
Figure 1 The spatial and temporal distribution of diarrhoea rates

Figure 1 The spatial and temporal distribution of diarrhoea rates
Figure 1. Flow diagram of participants recruited into the study.

Figure 1. Flow diagram of participants recruited into the study.
Figure 1. Scree plot for the exploratory factor analysis (EFA) of the Death Depression Scale (DDS). From: Development and psychometric evaluation of a.

Figure 1. Scree plot for the exploratory factor analysis (EFA) of the Death Depression Scale (DDS). From: Development and psychometric evaluation of a.
Figure 2. CONSORT flow diagram.

Figure 2. CONSORT flow diagram.
Table 3 Titers of antibody to hepatitis B surface antigen (anti-HBs) 2–4 weeks after the first vaccination From: Response to Hepatitis B Vaccine in HIV-1–Positive.

Table 3 Titers of antibody to hepatitis B surface antigen (anti-HBs) 2–4 weeks after the first vaccination From: Response to Hepatitis B Vaccine in HIV-1–Positive.
Figure 1. Period–cohort diagram.

Figure 1. Period–cohort diagram.
Figure 1. Disposition of study participants, by group. Data are no

Figure 1. Disposition of study participants, by group. Data are no
Figure 1. Forest plot: overall estimate

Figure 1. Forest plot: overall estimate
Table 6 The results of virus isolation tests before and after oseltamivir therapy. From: A Comparison of the Effectiveness of Oseltamivir for the Treatment.

Table 6 The results of virus isolation tests before and after oseltamivir therapy. From: A Comparison of the Effectiveness of Oseltamivir for the Treatment.
Figure 1 Inclusion criteria, exclusion criteria, and criteria for virologic failure. CDC, Centers for Disease Control and Prevention; ddC, zalcitabine;

Figure 1 Inclusion criteria, exclusion criteria, and criteria for virologic failure. CDC, Centers for Disease Control and Prevention; ddC, zalcitabine;
Figure 1. Programme provisions, eligibility, evaluation period and geographical coverage of programme over time From: Impact evaluation of free delivery.

Figure 1. Programme provisions, eligibility, evaluation period and geographical coverage of programme over time From: Impact evaluation of free delivery.
Figure 1. Shiga toxin–producing Escherichia coli (STEC) isolates by method of initial detection and STEC serotype, Connecticut, 2000–2009. From: Ten-Year.

Figure 1. Shiga toxin–producing Escherichia coli (STEC) isolates by method of initial detection and STEC serotype, Connecticut, 2000–2009. From: Ten-Year.
Figure 3. Examples of tweets classified as ridicule.

Figure 3. Examples of tweets classified as ridicule.
Figure 1. Conceptual framework.

Figure 1. Conceptual framework.
Figure 1. Logos appearing in the choice experiment

Figure 1. Logos appearing in the choice experiment
Figure 1. Selection of papers.

Figure 1. Selection of papers.
Table 1 Characteristics of study patients in survey of HIV infection in India. From: Natural History of Human Immunodeficiency Virus Disease in Southern.

Table 1 Characteristics of study patients in survey of HIV infection in India. From: Natural History of Human Immunodeficiency Virus Disease in Southern.
Figure 1. Conceptual model of well-being related to involvement in theatre. From: Theatre Involvement and Well-Being, Age Differences, and Lessons From.

Figure 1. Conceptual model of well-being related to involvement in theatre. From: Theatre Involvement and Well-Being, Age Differences, and Lessons From.

Similar presentations

Ads by Google